Compare XOMA & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XOMA | SGHT |
|---|---|---|
| Founded | 1981 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 308.6M | 282.9M |
| IPO Year | N/A | 2021 |
| Metric | XOMA | SGHT |
|---|---|---|
| Price | $27.59 | $4.08 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $60.60 | $9.08 |
| AVG Volume (30 Days) | 134.0K | ★ 333.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.16 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $77,363,000.00 |
| Revenue This Year | $76.93 | $13.54 |
| Revenue Next Year | $29.28 | $14.53 |
| P/E Ratio | $29.64 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.40 | $2.03 |
| 52 Week High | $39.92 | $9.24 |
| Indicator | XOMA | SGHT |
|---|---|---|
| Relative Strength Index (RSI) | 59.35 | 32.47 |
| Support Level | $23.92 | $3.99 |
| Resistance Level | $35.17 | $4.33 |
| Average True Range (ATR) | 1.47 | 0.36 |
| MACD | 0.26 | -0.10 |
| Stochastic Oscillator | 97.87 | 23.91 |
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.